Umecrine Cognition key facts
as of Oct 2026- Developer of pharmaceutical drugs designed to treat cognitive neurological disorders.
- Umecrine Cognition is valued at approximately $71.5M as of Oct 2026 (last reported valuation).
- It has raised $28.1M; the latest was Later Stage VC ($5.5M) in Jul 2025.
- Notable investors include Almi Invest, Norrlandsfonden, AB Ility, Fort Knox, KDventures — 9 tracked in total.
- Status: Privately Held (backing).
Umecrine Cognition's last reported valuation, Jul 2021. Nothing priced has surfaced since.
- ·Watch Umecrine Cognition: the Monday email on marks, rounds and moves
Umecrine Cognition funding rounds
No funding rounds for Umecrine Cognition are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Umecrine Cognition valuation
Umecrine Cognition's last reported valuation was $71.5 million in Jul 2021. No priced round, secondary trade or fund mark has surfaced since.
Umecrine Cognition investors
9 investors are on record for Umecrine Cognition, including Almi Invest, Norrlandsfonden, AB Ility and Fort Knox.
About Umecrine Cognition
Developer of pharmaceutical drugs designed to treat cognitive neurological disorders. The company offers drugs for the treatment of symptoms in the central nervous system related to chronic neuroinflammation, a brain distortion that can lead to severely impaired cognition and fatigue, enabling healthcare industries to directly address the neurocognitive signs and symptoms of hepatic encephalopathy.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2006
- Employees
- 3
- Website
- umecrinecognition.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.